Anticipating the "silver tsunami"

Prevalence trajectories and comorbidity burden among older cancer survivors in the United States

Shirley Bluethmann, Angela B. Mariotto, Julia H. Rowland

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Background: Cancer survivors are a growing population, due in large part to the aging of the baby boomer generation and the related "silver tsunami" facing the U.S. health care system. Understanding the impact of a graying nation on cancer prevalence and comorbidity burden is critical in informing efforts to design and implement quality cancer care for this population. Methods: Incidence and survival data from 1975 to 2011 were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program to estimate current cancer prevalence. SEER-Medicare claims data were used to estimate comorbidity burden. Prevalence projections were made using U.S. Census Bureau data and the Prevalence Incidence Approach Model, assuming constant future incidence and survival trends but dynamic projections of the U.S. population. Results: In 2016, there were an estimated 15.5 million cancer survivors living in the United States, 62% of whom were 65 years or older. The prevalent population is projected to grow to 26.1 million by 2040, and include 73% of survivors who are 65 years and older. Comorbidity burden was highest in the oldest survivors (those ≥85 years) and worst among lung cancer survivors. Conclusions: Older adults, who often present with complex health needs, now constitute the majority of cancer survivors and will continue to dominate the survivor population over the next 24 years. Impact: The oldest adults (i.e., those >75 years) should be priority populations in a pressing cancer control and prevention research agenda that includes expanding criteria for clinical trials to recruit more elderly participants and developing relevant supportive care interventions.

Original languageEnglish (US)
Pages (from-to)1029-1036
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume25
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Tsunamis
Silver
Survivors
Comorbidity
Neoplasms
Population
Incidence
SEER Program
Survival
Quality of Health Care
Censuses
Medicare
Lung Neoplasms
Epidemiology
Clinical Trials
Delivery of Health Care
Health

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

@article{b5ad233ffce946a18f685024898f026e,
title = "Anticipating the {"}silver tsunami{"}: Prevalence trajectories and comorbidity burden among older cancer survivors in the United States",
abstract = "Background: Cancer survivors are a growing population, due in large part to the aging of the baby boomer generation and the related {"}silver tsunami{"} facing the U.S. health care system. Understanding the impact of a graying nation on cancer prevalence and comorbidity burden is critical in informing efforts to design and implement quality cancer care for this population. Methods: Incidence and survival data from 1975 to 2011 were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program to estimate current cancer prevalence. SEER-Medicare claims data were used to estimate comorbidity burden. Prevalence projections were made using U.S. Census Bureau data and the Prevalence Incidence Approach Model, assuming constant future incidence and survival trends but dynamic projections of the U.S. population. Results: In 2016, there were an estimated 15.5 million cancer survivors living in the United States, 62{\%} of whom were 65 years or older. The prevalent population is projected to grow to 26.1 million by 2040, and include 73{\%} of survivors who are 65 years and older. Comorbidity burden was highest in the oldest survivors (those ≥85 years) and worst among lung cancer survivors. Conclusions: Older adults, who often present with complex health needs, now constitute the majority of cancer survivors and will continue to dominate the survivor population over the next 24 years. Impact: The oldest adults (i.e., those >75 years) should be priority populations in a pressing cancer control and prevention research agenda that includes expanding criteria for clinical trials to recruit more elderly participants and developing relevant supportive care interventions.",
author = "Shirley Bluethmann and Mariotto, {Angela B.} and Rowland, {Julia H.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1158/1055-9965.EPI-16-0133",
language = "English (US)",
volume = "25",
pages = "1029--1036",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

Anticipating the "silver tsunami" : Prevalence trajectories and comorbidity burden among older cancer survivors in the United States. / Bluethmann, Shirley; Mariotto, Angela B.; Rowland, Julia H.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 25, No. 7, 01.07.2016, p. 1029-1036.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anticipating the "silver tsunami"

T2 - Prevalence trajectories and comorbidity burden among older cancer survivors in the United States

AU - Bluethmann, Shirley

AU - Mariotto, Angela B.

AU - Rowland, Julia H.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background: Cancer survivors are a growing population, due in large part to the aging of the baby boomer generation and the related "silver tsunami" facing the U.S. health care system. Understanding the impact of a graying nation on cancer prevalence and comorbidity burden is critical in informing efforts to design and implement quality cancer care for this population. Methods: Incidence and survival data from 1975 to 2011 were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program to estimate current cancer prevalence. SEER-Medicare claims data were used to estimate comorbidity burden. Prevalence projections were made using U.S. Census Bureau data and the Prevalence Incidence Approach Model, assuming constant future incidence and survival trends but dynamic projections of the U.S. population. Results: In 2016, there were an estimated 15.5 million cancer survivors living in the United States, 62% of whom were 65 years or older. The prevalent population is projected to grow to 26.1 million by 2040, and include 73% of survivors who are 65 years and older. Comorbidity burden was highest in the oldest survivors (those ≥85 years) and worst among lung cancer survivors. Conclusions: Older adults, who often present with complex health needs, now constitute the majority of cancer survivors and will continue to dominate the survivor population over the next 24 years. Impact: The oldest adults (i.e., those >75 years) should be priority populations in a pressing cancer control and prevention research agenda that includes expanding criteria for clinical trials to recruit more elderly participants and developing relevant supportive care interventions.

AB - Background: Cancer survivors are a growing population, due in large part to the aging of the baby boomer generation and the related "silver tsunami" facing the U.S. health care system. Understanding the impact of a graying nation on cancer prevalence and comorbidity burden is critical in informing efforts to design and implement quality cancer care for this population. Methods: Incidence and survival data from 1975 to 2011 were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program to estimate current cancer prevalence. SEER-Medicare claims data were used to estimate comorbidity burden. Prevalence projections were made using U.S. Census Bureau data and the Prevalence Incidence Approach Model, assuming constant future incidence and survival trends but dynamic projections of the U.S. population. Results: In 2016, there were an estimated 15.5 million cancer survivors living in the United States, 62% of whom were 65 years or older. The prevalent population is projected to grow to 26.1 million by 2040, and include 73% of survivors who are 65 years and older. Comorbidity burden was highest in the oldest survivors (those ≥85 years) and worst among lung cancer survivors. Conclusions: Older adults, who often present with complex health needs, now constitute the majority of cancer survivors and will continue to dominate the survivor population over the next 24 years. Impact: The oldest adults (i.e., those >75 years) should be priority populations in a pressing cancer control and prevention research agenda that includes expanding criteria for clinical trials to recruit more elderly participants and developing relevant supportive care interventions.

UR - http://www.scopus.com/inward/record.url?scp=84977109186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977109186&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-16-0133

DO - 10.1158/1055-9965.EPI-16-0133

M3 - Article

VL - 25

SP - 1029

EP - 1036

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -